Profilo
Paul McInulty is currently the Senior Vice President-Regulatory Affairs at Arvinas, Inc. Prior to this, he worked as the Vice President-Therapeutic Head & Hematology at Bristol Myers Squibb Co. and as the Vice President-Regulatory Affairs at Celgene Corp.
He completed his undergraduate degree at The University of Sheffield.
Posizioni attive di Paul McInulty
| Società | Posizione | Inizio |
|---|---|---|
| ARVINAS, INC. | General Counsel | 03/10/2022 |
Precedenti posizioni note di Paul McInulty
| Società | Posizione | Fine |
|---|---|---|
| CELGENE | General Counsel | - |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Formazione di Paul McInulty
| The University of Sheffield | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| ARVINAS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
- Borsa valori
- Insiders
- Paul McInulty
